A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain (Q39334010)

11 September 2017

title

A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain (English)

1 reference

11 September 2017

0 references

8

Kenneth E Truitt

1 reference

11 September 2017

1

James B Moberly

1 reference

11 September 2017

Jianbo Xu

2

1 reference

11 September 2017

Paul J Desjardins

3

1 reference

11 September 2017

Stephen E Daniels

4

1 reference

11 September 2017

Donald P Bandy

5

1 reference

11 September 2017

Janet E Lawson

6

1 reference

11 September 2017

Allison J Link

7

1 reference

11 September 2017

publication date

1 March 2007

1 reference

11 September 2017

published in

Clinical Therapeutics

1 reference

11 September 2017

volume

29

1 reference

11 September 2017

issue

3

1 reference

11 September 2017

page(s)

399-412

1 reference

Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Cyclooxygenase inhibition and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Coxibs and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

1 reference

7 January 2021

Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Efficacy and tolerability of the specific cyclooxygenase-2 inhibitor DFP compared with naproxen sodium in patients with postoperative dental pain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Conventional and extended-release etodolac for postsurgical dental pain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Alveolitis sicca dolorosa after removal of impacted mandibular third molars

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Alveolar osteitis after surgical removal of impacted mandibular third molars. Identification of the patient at risk

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

Individual patient meta-analysis of single-dose rofecoxib in postoperative pain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980078-6

7 January 2021

10.1016/S0149-2918(07)80078-6

Identifiers

DOI

1 reference

11 September 2017

1 reference